Yesterday, the Australian Self Medication Industry (ASMI) submitted to the TGA their response to the consultation on the proposed criteria and guidance for Appendix M.

ASMI supports the creation of Appendix M as it will provide a new mechanism to implement consumer safeguards and pharmacist guidance (should they be necessary) when switching prescription (Schedule 4) medicines to non-prescription (Schedule 3) medicines.

Increasing access to medicines where appropriate will lead to an empowered consumer and result in greater Self Care. This will advance consumer health and ease the burden on the existing healthcare system.

The ASMI submission can be found here.